Q2 2026 13F · SEC CIK 1055951

Orbimed Advisors LLC

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $5.3B
Reported positions: 117
Top holdings a year, 3 yrs: +15.1%
Assets under management: $20.6B

Orbimed Advisors LLC is a hedge fund that reported 117 positions worth $5.3B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Edgewise Therapeutics Inc (EWTX, 12.0%), Enliven Therapeutics Inc (ELVN, 6.5%), Eli Lilly & Co (LLY, 5.9%). A portfolio copying its top holdings returned 15.1% a year over the last 3 years, against 22.3% for the S&P 500.

Orbimed Advisors LLC holdings largest 50 of 117 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Orbimed Advisors LLC 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
EWTXEdgewise Therapeutics Inc	12.0%	11.1%	15,518,492	+0.0%	$630.5M
ELVNEnliven Therapeutics Inc	6.5%	7.1%	6,776,632	-14.9%	$343.9M
LLYEli Lilly & Co	5.9%	4.9%	257,900	+8.9%	$309.3M
MBXMbx Biosciences Inc	3.6%	2.5%	3,428,736	-5.7%	$189.3M
SVASinovac Biotech Ltd	3.5%	4.2%	2,718,735	+0.0%	$184.5M
AZNAstrazeneca PLC	3.2%	3.0%	915,700	+36.6%	$171.1M
GPCRStructure Therapeutics F Unspo	2.3%	1.6%	2,209,400	+49.7%	$118.6M
829401108Sionna Therapeutics Inc	2.1%	3.2%	2,555,877	-27.6%	$112.4M
CRVSCorvus Pharmaceuticals Inc Com	2.0%	2.4%	7,165,006	+0.0%	$107.0M
AVBPArrivent Biopharma Inc	2.0%	1.6%	3,027,328	+0.0%	$105.2M
GHGuardant Health Inc	1.7%	0.9%	583,700	+34.1%	$87.6M
ARGNFArgenx SE	1.6%	2.3%	92,880	-32.2%	$86.2M
MRKMerck & Co Inc	1.6%	1.8%	663,400	+0.0%	$85.2M
QUREUniqure NV	1.6%	0.8%	1,807,486	-15.4%	$83.3M
PRAXPraxis Precision Medicines I	1.5%	1.3%	230,100	+33.4%	$77.0M
EWEdwards Lifesciences Corp	1.4%	2.2%	834,900	-32.2%	$75.5M
PRLDPrelude Therapeutics Inc	1.4%	0.8%	13,724,571	+25.8%	$73.2M
ABVXAbivax SA	1.4%	1.2%	546,522	+17.4%	$72.8M
DYNDyne Therapeutics Inc	1.4%	1.2%	3,235,684	+10.9%	$71.9M
NTRANatera Inc	1.4%	1.2%	262,000	+0.0%	$71.1M
CGONCg Oncology Inc	1.3%	1.5%	972,800	+2.6%	$69.1M
UNHUnitedhealth Group Inc	1.3%	—	161,100	—	$67.0M
SPRYArs Pharmaceuticals Inc	1.3%	1.5%	8,288,510	+0.0%	$66.4M
ASNDAscendis Pharma A/s	1.2%	—	244,456	—	$65.2M
HUMHumana Inc	1.2%	—	164,100	—	$65.2M
COGTCogent Biosciences Inc	1.2%	—	1,681,300	—	$65.1M
BSXBoston Scientific Corp	1.2%	3.4%	1,483,200	-37.7%	$63.3M
ISRGIntuitive Surgical Inc	1.2%	2.2%	157,900	-24.3%	$62.8M
MLYSMineralys Therapeutics Inc	1.1%	1.3%	2,110,300	+2.8%	$56.9M
ODTXOdyssey Therapeutics, Inc.	1.1%	—	3,001,198	—	$56.2M
XENEXenon Pharmaceuticals Inc	1.0%	1.4%	892,471	-15.8%	$53.9M
ARQTArcutis Biotherapeutics Inc	1.0%	—	2,042,000	—	$53.5M
BMYBristol-Myers Squibb Co	1.0%	1.3%	925,000	+0.0%	$53.3M
QTTBQ32 Bio Inc	1.0%	—	4,127,987	—	$52.6M
SYKStryker Corporation	1.0%	1.4%	159,100	-12.8%	$50.1M
CAICaris Life Sciences Inc	0.9%	1.1%	2,806,811	+0.0%	$50.0M
TMOThermo Fisher Scientific Inc	0.9%	0.5%	90,700	+95.1%	$45.5M
PVLAPalvella Therapeutics Inc Ne	0.8%	—	292,360	—	$44.7M
ELVElevance Health Inc Formerly	0.8%	0.8%	114,700	+0.0%	$44.4M
STTKShattuck Labs Inc	0.8%	0.9%	6,306,127	+0.0%	$43.8M
UPBUpstream Bio Inc	0.7%	1.2%	5,693,589	+0.0%	$39.4M
CRNXCrinetics Pharmaceuticals in	0.7%	0.8%	999,000	+0.0%	$37.4M
RYTMRhythm Pharmaceuticals Inc	0.7%	0.6%	322,900	+2.8%	$35.9M
SNDXSyndax Pharmaceuticals Inc	0.6%	0.5%	1,542,000	+60.2%	$33.7M
FBRXForte Biosciences Inc	0.6%	0.7%	1,577,705	+31.8%	$33.5M
CMPXCompass Therapeutics Inc	0.6%	1.8%	15,219,994	+0.0%	$33.3M
NKTRNektar Therapeutics	0.6%	—	465,346	—	$32.5M
KRYSKrystal Biotech Inc	0.6%	—	83,200	—	$30.9M
000000000Koninklijke Philips N V	0.6%	0.5%	5,680,186	-8.5%	$30.3M
AXSMAxsome Therapeutics, Inc.	0.5%	0.8%	117,578	-45.0%	$28.8M

What Orbimed Advisors LLC bought and sold in Q2 2026, against Q1 2026.

New positions

Q1 2026's filing was too long to tell new positions apart.

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: +7.1% /yr; S&P 500 +11.7%
3 years: +15.1% /yr; S&P 500 +22.3%
5 years: -2.8% /yr; S&P 500 +10.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$5.3B	117
Q1 2026	$4.4B	105
Q4 2025	$4.9B	104
Q3 2025	$4.2B	98
Q2 2025	$4.0B	97
Q1 2025	$4.2B	106
Q4 2024	$4.8B	111
Q3 2024	$5.5B	109
Q2 2024	$5.0B	108
Q1 2024	$5.4B	112
Q4 2023	$5.0B	109
Q3 2023	$4.7B	120

Questions about Orbimed Advisors LLC's portfolio

What stocks does Orbimed Advisors LLC own?

Orbimed Advisors LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 117 positions worth $5.3B. The largest are Edgewise Therapeutics Inc (EWTX) at 12.0%, Enliven Therapeutics Inc (ELVN) at 6.5%, Eli Lilly & Co (LLY) at 5.9%, Mbx Biosciences Inc (MBX) at 3.6% and Sinovac Biotech Ltd (SVA) at 3.5%.

What did Orbimed Advisors LLC buy last quarter?

In Q2 2026, Orbimed Advisors LLC added Thermo Fisher Scientific Inc (TMO) (+95.1% shares), Syndax Pharmaceuticals Inc (SNDX) (+60.2% shares) and Structure Therapeutics F Unspo (GPCR) (+49.7% shares), compared with its Q1 2026 filing.

What did Orbimed Advisors LLC sell last quarter?

In Q2 2026, Orbimed Advisors LLC cut from its top 50 Disc Medicine Inc (IRON), cut from its top 50 Pfizer Inc (PFE), cut from its top 50 Danaher Corp Del (DHR), cut from its top 50 Ascendis Pharma A/s, cut from its top 50 Alnylam Pharmaceuticals Inc (ALNY), Axsome Therapeutics, Inc. (AXSM) (-45.0% shares), Boston Scientific Corp (BSX) (-37.7% shares) and Edwards Lifesciences Corp (EW) (-32.2% shares), compared with its Q1 2026 filing.

How has Orbimed Advisors LLC's portfolio performed?

A portfolio copying Orbimed Advisors LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +15.1% a year over the last 3 years, against +22.3% for the S&P 500. Over 1 year: +7.1% against +11.7%. Over 5 years: -2.8% a year against +10.6%.

When is Orbimed Advisors LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. Orbimed Advisors LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Orbimed Advisors LLC manage?

Orbimed Advisors LLC reported $20.6B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $5.3B.